IN BRIEF 1: Traumakine
READY FOR SALE? IT HAS BEEN REMOVED FROM THE PIPE-LINE. " Faron will revolutionize intensive care" BUT: It is a MULTIFUNCTIONAL DRUG = potential. Traumakine® was originally developed for the treatment of acute respiratory failure syndrome (ADRS). It was once statused as an ‘orphan’. It is currently being tested for intensive care for people infected with COVID. According to Faron, the patients participating in the test need little additional oxygen and no help from ventilators. Some of the subjects receive Traumakine and some receive cortisone treatment. https://www.mordorintelligence.com/industry-reports/acute-respiratory-distress-syndrome-treatment-market Acute Respiratory Distress Syndrome Treatment Market Size & Share Analysis - The market exhibits moderate fragmentation . Medtronic, GE Healthcare, and Philips anchor mechanical ventilation while Hamilton Medical pioneers adaptive feedback. Faron Pharmaceuticals, Mesoblast, and Athersys fuel the immuno...